Form D · Biotechnology
ANCORA PHARMACEUTICALS INC
Medford, MA · CIK 0001401177
Offering snapshot reported Nov 24, 2009 · SEC filing
- Reported sold
- $800K Indefinite offering
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $800K Reported outside-investor minimum
- First sale
- Nov 9, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 24, 2009 | Initial | $800,000 | No comparison | 1 | SEC filing |
| May 18, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-103768
Source: Form D, filed Nov 24, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Barry Buckland | Director |
| Doug Jamison | Director |
| John Pena | Director, Executive |
| Carmichael Roberts | Director |
| Peter Seeberger | Director |
| Mitsi Ushio | Director |
| Karl White | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
200 Boston Ave Suite 4975
Medford, MA, 02155
Medford, MA, 02155